TY - JOUR
T1 - An in vivo mouse model for human prostate cancer metastasis
AU - Havens, Aaron M.
AU - Pedersen, Elisabeth A.
AU - Shiozawa, Yusuke
AU - Ying, Chi
AU - Jung, Younghun
AU - Sun, Yanxi
AU - Neeley, Chris
AU - Wang, Jincheng
AU - Mehra, Rohit
AU - Keller, Evan T.
AU - McCauley, Laurie K.
AU - Loberg, Robert D.
AU - Pienta, Kenneth J.
AU - Taichman, Russell S.
N1 - Funding Information:
Address all correspondence to: Russell S. Taichman, Department of Periodontics and Oral Medicine, University of Michigan School of Dentistry, 1011 North University Avenue, Ann Arbor, MI 48109-1078. E-mail: [email protected] 1This work was directly supported by the Charles Eliot Ware Memorial Fellowship (A.M. Havens), Pediatric Oncology Research Fellowship (Y. Shiozawa), CA93900 (L.K. McCauley, E.T. Keller, K.J. Pienta, and R.S. Taichman), the Department of Defense PC060857 (R.S. Taichman), P50 CA69568 (K.J. Pienta), U19 CA113317 (K.J. Pienta), and 2006 and 2007 awards from the Prostate Cancer Foundation (R.S. Taichman and K.J. Pienta). K.J. Pienta receives support as an American Cancer Society Clinical Research Professor. 2This work is dedicated to Leslie Taichman. May she heal quickly. 3This article refers to a supplementary material, which is designated by Figure W1 and is available online at www.neoplasia.com. Received 13 January 2008; Revised 29 January 2008; Accepted 30 January 2008 Copyright © 2008 Neoplasia Press, Inc. All rights reserved 1522-8002/08/$25.00 DOI 10.1593/neo.08154
PY - 2008/4
Y1 - 2008/4
N2 - We developed a sensitive real-time polymerase chain reaction (QPCR) assay that allows us to track early lodging/homing events in vivo. We used this technology to develop a metastasis assay of human prostate cancer (PCa) growth in severe combined immunodeficient mice. For this purpose, marked human PCa cell lines were implanted subcutaneously or in the prostate (orthotopically) of severe combined immunodeficient mice as models of primary tumors. Mice were then sacrificed at various time points, and distant tissues were investigated for the presence of metastatic cells. At 3 weeks, a number of tissues were recovered and evaluated by QPCR for the presence of metastatic cells. The data demonstrate that several PCa cell lines are able to spread from the primary lesion and take up residence in distant sites. If the primary tumors were resected at 3 weeks, in several cases, metastastic lesions were identified over the course of 9 months. We propose that this new model may be particularly useful in exploring the molecular events in early metastasis, identifying the metastatic niche, and studying issues pertaining to dormancy.
AB - We developed a sensitive real-time polymerase chain reaction (QPCR) assay that allows us to track early lodging/homing events in vivo. We used this technology to develop a metastasis assay of human prostate cancer (PCa) growth in severe combined immunodeficient mice. For this purpose, marked human PCa cell lines were implanted subcutaneously or in the prostate (orthotopically) of severe combined immunodeficient mice as models of primary tumors. Mice were then sacrificed at various time points, and distant tissues were investigated for the presence of metastatic cells. At 3 weeks, a number of tissues were recovered and evaluated by QPCR for the presence of metastatic cells. The data demonstrate that several PCa cell lines are able to spread from the primary lesion and take up residence in distant sites. If the primary tumors were resected at 3 weeks, in several cases, metastastic lesions were identified over the course of 9 months. We propose that this new model may be particularly useful in exploring the molecular events in early metastasis, identifying the metastatic niche, and studying issues pertaining to dormancy.
UR - https://www.scopus.com/pages/publications/41649086938
UR - https://www.scopus.com/pages/publications/41649086938#tab=citedBy
U2 - 10.1593/neo.08154
DO - 10.1593/neo.08154
M3 - Article
C2 - 18392141
AN - SCOPUS:41649086938
SN - 1522-8002
VL - 10
SP - 371
EP - 379
JO - Neoplasia
JF - Neoplasia
IS - 4
ER -